⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DSGN News
Design Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
DSGN
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates
globenewswire.com
DSGN
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates
globenewswire.com
DSGN
Design Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com
DSGN
Convera任命行业资深高管Meaghan Riley为首席商务官，推动商业规模化发展并拓展收入增长空间
businesswire.com
GOOGL
DSGN
SAP
Design Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com
DSGN
Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results
globenewswire.com
DSGN